RLYB
Rallybio CorpPrice
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
- S Feb 23 1 insider sell $4.0K at $5.06
- B May 4 to May 19 8 days of insider buys: $4.2M by 1 insider, avg $13.98
- R May 4 Candid Therapeutics terminated its merger agreement with Rallybio to…
- R Jun 1 Rallybio Corp (RLYB) filed this 425 communication to confirm the def…
- R Jun 1 Rallybio Corp (RLYB) entered into a definitive merger agreement to b…
- R Jul 15 Rallybio Corp (RLYB) filed an S-4 registration statement for a propo…
- X Jul 31 Short interest falls 62.7% to 63.5K
- R Oct 14 Rallybio filed Amendment No. 4 to its S-4 registration statement for…
Signal stack
Where each data set points today.
- InsidersBULLISH
1 insider bought $4.2M at an average $13.98. 1 insider sold $4.0K. Price is 14% above their cost.
- InstitutionsMIXED
Q2 2026: 4 added (0 new), 2 trimmed or exited.
- EstimatesFLAT
Current-quarter EPS estimate −$1.440 → −$1.440 over 90 days.
- Short sellersCOVERING
Short interest −16.8% to 41.0K shares. 7.4 days to cover, ≈0.8% of shares.
- TrendDOWNTREND
5% below its 50-day average.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | ADD | $3.2M |
| VANGUARD CAPITAL MANAGEMENT LLC | ADD | $2.8M |
| CITADEL ADVISORS LLC | DOUBLED | $1.2M |
| BlackRock, Inc. | ADD | $485.3K |
| UBS Group AG | NEAR_EXIT | $2.3K |
| JPMORGAN CHASE & CO | NEAR_EXIT | $145.00 |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
last action Apr 2025| Date | Firm | Rating |
|---|---|---|
| Apr 15, 2025 | Jones Trading DOWNGRADE | Hold |
| Apr 9, 2025 | HC Wainwright & Co. DOWNGRADE | Neutral |
| Mar 17, 2025 | HC Wainwright & Co. REITERATE | Buy |
| Feb 12, 2025 | HC Wainwright & Co. REITERATE | Buy |
| Jan 13, 2025 | HC Wainwright & Co. REITERATE | Buy |
| Dec 3, 2024 | HC Wainwright & Co. REITERATE | Buy |
Insider ledger
Form 4| Date | Insider | Type | Value |
|---|---|---|---|
| Oct 16, 2026 | Soteropoulos Paula Director | EXERCISE | $8.5K |
| Oct 16, 2026 | Boudreau Helen M Director | EXERCISE | $31.5K |
| Oct 12, 2026 | Hopfner Robert Lorne Director | EXERCISE | $69.9K |
| Oct 12, 2026 | Hopfner Robert Lorne Director | EXERCISE | $8.5K |
| Oct 12, 2026 | Hopfner Robert Lorne Director | EXERCISE | $31.5K |
| Oct 9, 2026 | Lieber Jonathan I Chief Financial Officer | EXERCISE | $23.8K |
| Oct 6, 2026 | Uden Stephen Chief Executive Officer | EXERCISE | $136.5K |
| Sep 29, 2026 | Lieber Jonathan I Chief Financial Officer | EXERCISE | $30.4K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$1.44 | -$1.44–-$1.44 | +0.0% | $0.00 |
| Next Q | -$1.60 | -$1.60–-$1.60 | +0.0% | $0.00 |
| Current FY | -$5.52 | -$5.52–-$5.52 | -2.2% | $0.00 |
| Next FY | -$3.60 | -$3.60–-$3.60 | +0.0% | $0.00 |
Short side
FINRA· Oct 15, 2026SecBot reports
8 filings · 2 bullish · 0 bearish · 1 mixed · 5 neutral- NEUTRAL 425Oct 26, 2026
Rallybio Corp declared an estimated $82.7 million special cash distribution ($13.56 per share) in…
The stockholder vote on November 4 is the key catalyst; approval is required for the cash distribution and merger to proceed. The ex-dividend date on the closing date means the stock price will…
- NEUTRAL 8-KOct 26, 2026
Rallybio Corp's board declared a special cash distribution of approximately $82.7 million ($13.56…
The cash distribution effectively returns substantially all of Rallybio's net cash to shareholders ahead of the merger close. The merger's completion and the distribution are contingent on the…
- NEUTRAL EFFECTOct 16, 2026
The SEC declared effective Rallybio Corp's S-4 registration statement (File No. 333-297483) on…
The S-4 effectiveness signals that a merger or acquisition transaction is progressing toward closing. Monitor for the definitive proxy/prospectus and shareholder vote date. The absence of pricing or…
- NEUTRAL S-4/AOct 14, 2026
Rallybio filed Amendment No. 4 to its S-4 registration statement for the proposed reverse merger…
The S-4/A filing advances the merger toward the stockholder vote. The key binary catalyst is the Rallybio stockholder meeting — if Proposals 1-3 pass, the merger closes and RLYB shares convert to…
All RLYB filing & press-release reports (8)
- 425 reportOct 26, 2026
- 8-K reportOct 26, 2026
- EFFECT reportOct 16, 2026
- S-4/A reportOct 14, 2026
- S-4 reportJul 15, 2026
- 425 reportJun 1, 2026
- 8-K reportJun 1, 2026
- 8-K reportMay 4, 2026